WSJ – Researchers Ready Lab-Grown Covid-19 Delta Variant for Human Trials August 27, 2021 – Posted in: Blog, Open Orphan (ORPH)

U.K. company is growing the highly contagious variant under tight lab controls for use in challenge studies Scientists have coaxed the Delta strain to mature, said Andrew Catchpole, chief scientiic oficer of trial partner hVivo. PHOTO: HVIVO SERVICES LIMITED by Jenny Strasburg – Wall Street Journal LONDON—While the rest of the world is trying to stamp out the Covid-19 Delta variant, British researchers are making progress growing a carefully controlled batch in a lab that…

Open Orphan #ORPH – Collaboration Agreement with HIC-VAC and Wellcome Trust November 19, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan, a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce that its subsidiary hVIVO has been selected to lead a consortium, on behalf of HIC-Vac, an international network of researchers who are developing human infection challenge (HIC) studies to accelerate the development of vaccines against pathogens,and the Wellcome Trust, to generate regulatory style guidelines…

Open Orphan #ORPH: The Times – Inside Story of coronavirus battlers. The Sun – We salute the unsung key workers. April 27, 2020 – Posted in: Open Orphan (ORPH)

Inside stories of coronavirus battlers Aerogen, Hibergene, Open Orphan and Nearform Ireland was placed sixth last week in a list of nations ranked on their response to the Covid-19 crisis in terms of innovation. The league table was compiled by StartupBlink, a Swiss-Israeli company that collates data on start-ups; the United Nations-backed Health Innovation Index; the Moscow Agency of Innovations; and partners such as tech database provider Crunchbase. While the Republic has punched above its…

Open Orphan #ORPH – Development of the World’s First Human Coronavirus Challenge Study Model March 9, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan, the rapidly growing specialist Clinical Research Organisation (“CRO”) pharmaceutical services company whose London-based subsidiary hVIVO is the world leader in the provision of virology and vaccine challenge study services, is pleased to announce that it has commenced the development of the world’s first commercial human coronavirus challenge study model, also known as a Controlled Human Infection Model (CHIM). The Company has Europe’s only 24-bedroom quarantine clinic with onsite virology lab where the challenge model…

WSJ – Researchers Ready Lab-Grown Covid-19 Delta Variant for Human Trials August 27, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan #ORPH – Collaboration Agreement with HIC-VAC and Wellcome Trust November 19, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan #ORPH: The Times – Inside Story of coronavirus battlers. The Sun – We salute the unsung key workers. April 27, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan #ORPH – Development of the World’s First Human Coronavirus Challenge Study Model March 9, 2020 – Posted in: Open Orphan (ORPH)

Address

Contact

Social

LEGAL